NCT03855384 - Study of TQB2450 in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck（R/M SCCHN） | Biotech Hunter

Enrollment

334

Participants

Timeline

Start Date

June 11, 2019

Primary Completion Date

December 31, 2020

Study Completion Date

May 30, 2021

Conditions

Squamous Cell Carcinoma of the Head and Neck

Interventions

DRUG

TQB2450+cisplatin or carboplatin + 5-Fluorouracil (5-FU)

TQB2450 1200mg IV ，cisplatin 75 mg/m\^2 IV or carboplatin AUC 5 IV on Day 1 of each week in 3-week cycles (6 cycle maximum); plus 5-FU 750 mg/m\^2/day IV continuous from Day 1-5 of each 3- week cycle (6 cycle maximum).

DRUG

placebo+cisplatin or carboplatin + 5-Fluorouracil (5-FU)

placebo 1200mg IV ，cisplatin 75 mg/m\^2 IV or carboplatin AUC 5 IV on Day 1 of each week in 3-week cycles (6 cycle maximum); plus 5-FU 750 mg/m\^2/day IV continuous from Day 1-5 of each 3- week cycle (6 cycle maximum).

Trial Locations (1)

Unknown

RECRUITING

Shanghai East Hospital, Shanghai